Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

458.96 -4.52 (-0.98%)
Streaming Delayed Price Updated: 9:43 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
News headline image
This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy? ↗
It's been an unusually bad year for this drugmaker, but it's essential to look beyond that. 
Via The Motley Fool
Topics Law Enforcement Stocks
News headline image
2 Beaten-Down Stocks With Incredible Upside Potential ↗
These stocks should be able to rebound strongly. 
Via The Motley Fool
News headline image
What's Wrong With Vertex Pharmaceuticals Stock? ↗
Shares of the pharma company are down 17% in the past 12 months. 
Via The Motley Fool
News headline image
2 Nasdaq 100 Stocks to Consider Right Now and 1 Facing Challenges
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
News headline image
Vertex Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Trump 2.0 At 200 Days: Palantir Surges, Tesla Slumps ↗
Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days. 
Via Benzinga
Topics Government Stocks
News headline image
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns ↗
This biotech's innovative approach could pay rich dividends down the road. 
Via The Motley Fool
News headline image
3 Fantastic Growth Stocks to Buy in August ↗
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years. 
Via The Motley Fool
News headline image
Is This Beaten-Down Stock a Buy on the Dip? ↗
It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point. 
Via The Motley Fool
News headline image
2 Growth Stocks That Are No-Brainer Buys Right Now ↗
These stocks have outperformed broader equities over the past decade and still have room to run. 
Via The Motley Fool
News headline image
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the... 
Via StockStory
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio? ↗
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly. 
Via Benzinga
News headline image
The Smartest Growth Stocks to Buy With $1,000 Right Now ↗
There's no guarantee that any stock will beat the market, but the chances look good for these three. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
5 Top Stocks to Buy in August ↗
Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Unusual volume S&P500 stocks in Thursday's session ↗
Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below. 
Via Chartmill
News headline image
The Best Stocks to Invest $1,000 In Right Now ↗
Market volatility could increase in the months ahead, but these stocks should hold up well. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
Which S&P500 stocks have an unusual volume on Wednesday? ↗
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Strong Affordable Growth Pick with Solid Fundamentals ↗
Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors. 
Via Chartmill
News headline image
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip ↗
There's more good news than bad news for this big biotech stock. 
Via The Motley Fool
Topics Earnings
News headline image
Market Monitor News August 06 BMO - Wall Street Slides as Services Sector Falters, but Palantir Rockets Past Expectations ↗
A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red. 
Via Chartmill
Topics Economy
News headline image
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial.... 
Via StockStory
Topics Artificial Intelligence
News headline image
Top S&P500 movers in Tuesday's session ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
Weakness In Vertex Stock Seen As Buying Opportunity ↗
Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales. 
Via Benzinga
News headline image
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results ↗
 
Via Benzinga
News headline image
Stock Market Rollercoaster: Wall Street Navigates Sharp Swings and Rebounds in Early August
The financial markets have been on a tumultuous ride in early August 2025, experiencing a dramatic "see-saw" pattern that has left investors both wary and hopeful. Following a sharp decline at the... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.